Obesity / Overweight – Unmet Need – Unmet Need – Obesity (US/EU)
The demand for safe and effective obesity drugs is increasing due to the rising prevalence of obesity and the growing interest in incretin therapies, whose efficacy is approaching that of bariatric surgery. In recent times, therapies that mimic the effects of GLP-1 and GIP peptides—natural gut hormones that regulate appetite and energy metabolism—have established new benchmarks for weight-loss drugs and are poised to reshape the obesity landscape in the coming years. Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound / Mounjaro (tirzepatide) are the most advanced antiobesity therapies, providing notably greater weight-loss efficacy than Novo Nordisk’s Saxenda. Older agents, such as phentermine, Contrave, Qsymia, and Xenical, are losing ground as preferred products despite their lower cost. In this report, we ask endocrinologists to evaluate and compare current antiobesity drugs. We also discuss the attributes that new antiobesity drugs should exhibit to serve the obese population and gain a competitive edge in the rapidly growing obesity market.
QUESTIONS ANSWERED
- How do endocrinologists rate current antiobesity drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound / Mounjaro?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What trade-offs across different clinical attributes and prices are needed from new drugs to be preferred by endocrinologists?
- How can dosing frequency, route of administration, cardiorenal benefit, and weight-loss efficacy influence physician preference?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European endocrinologists fielded in March 2025
Key companies: Novo Nordisk, Eli Lilly, Currax Pharmaceuticals, Vivus, Cheplapharm, H2-Pharma
Key drugs: Wegovy, Zepbound / Mounjaro, Contrave / Mysimba, Qsymia, Xenical
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
KEY FEATURE
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
